Skip to main content
. Author manuscript; available in PMC: 2023 Aug 19.
Published in final edited form as: ACS Chem Biol. 2022 Jul 14;17(8):2188–2200. doi: 10.1021/acschembio.2c00330

Figure 7. Compounds in clinical trials inhibit EBP.

Figure 7.

(A), (C), (E) Percentage of MBP+oligodendrocytes generated from OPCs following treatment with bioactive small molecules. OPCs in (A) were treated with quetiapine at 3 μM while those in (C) and (E) were treated with bazedoxifene and GSK 239512 in dose response as shown. n=4 wells per condition, except DMSO, amorolfine, and TASIN-1, n=8 wells, with >1,000 cells analyzed per well. (B), (D), (F) GC-MS based quantification of zymostenol, and zymosterol levels in OPCs treated for 24 h with the indicated screening hits at their effective concentrations. n=2 wells per condition. (G) Quantification of EBP enzymatic activity in a biochemical assay. All treatments 10 μM. n=2 independent enzymatic assays. Bars indicate mean and error bars represent s.d. Results in (C) represent two independent experiments.